PARP14

Protein mono-ADP-ribosyltransferase PARP14

36,104 patent compounds predicted against PARP14, 23,696 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL347934	0.55	15/20
SCHEMBL208113	0.60	13/20
SCHEMBL51674	0.58	13/20
SCHEMBL191654	0.58	13/20
SCHEMBL147411	0.53	13/20
SCHEMBL417017	0.51	13/20
SCHEMBL190688	0.52	12/20
SCHEMBL192834	0.52	12/20
SCHEMBL413461	0.49	12/20
SCHEMBL427029	0.62	11/20
SCHEMBL415890	0.50	11/20
SCHEMBL442417	0.46	11/20
SCHEMBL412773	0.44	11/20
SCHEMBL467119	0.41	11/20
SCHEMBL257857	0.53	10/20
SCHEMBL38828	0.51	10/20
SCHEMBL208888	0.51	10/20
SCHEMBL348241	0.52	9/20
SCHEMBL147834	0.54	8/20
SCHEMBL411756	0.54	8/20

Germline variants in PARP14 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PARP14 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PARP14 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation	PHASE4	ACTIVE_NOT_RECRUITING
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients	PHASE3	COMPLETED
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)	PHASE2	RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer	PHASE2	COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Olaparib In Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
Pre-Operative Radiation and Veliparib for Breast Cancer	PHASE1	COMPLETED
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	PHASE1	ACTIVE_NOT_RECRUITING
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors	PHASE1	WITHDRAWN
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Sirtuin1 in COVID19 Patients	nan	UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PARP14 binder may also engage these)

Protein	Name	Similarity
Q2EMV9	—	0.997	Q2EMV9 →
Q8TDB6	—	0.993	Q8TDB6 →
Q3B7D9	—	0.992	Q3B7D9 →
Q3UIR3	—	0.990	Q3UIR3 →
Q69Z37	—	0.987	Q69Z37 →
Q91VF2	—	0.987	Q91VF2 →
Q6ZSC3	—	0.986	Q6ZSC3 →
O70145	—	0.986	O70145 →
Q1MT80	—	0.985	Q1MT80 →
Q09YK6	—	0.985	Q09YK6 →
Q07DZ7	—	0.985	Q07DZ7 →
Q60462	—	0.985	Q60462 →
Q3MHH2	—	0.984	Q3MHH2 →
Q8BMD7	—	0.984	Q8BMD7 →
P21621	—	0.984	P21621 →
Q2QLG0	—	0.983	Q2QLG0 →
Q8CAS9	—	0.983	Q8CAS9 →
P46648	—	0.983	P46648 →
Q2TAA8	—	0.983	Q2TAA8 →
Q640K1	—	0.983	Q640K1 →
Q5U2X2	—	0.983	Q5U2X2 →
P85967	—	0.983	P85967 →
Q7TPV4	—	0.983	Q7TPV4 →
Q9D2K4	—	0.983	Q9D2K4 →
C6FG12	—	0.983	C6FG12 →
F2Z461	—	0.983	F2Z461 →
Q8K337	—	0.983	Q8K337 →
Q2IBB1	—	0.983	Q2IBB1 →
Q63713	—	0.983	Q63713 →
P58069	—	0.982	P58069 →